Skip to content 
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. more
| Time Frame | AARD | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.01% | 1.07% | 0.74% |
| 1-Month Return | -18.49% | 1.46% | 1.28% |
| 3-Month Return | 20.94% | 3.51% | 3.6% |
| 6-Month Return | 24.39% | 15.29% | 7.31% |
| 1-Year Return | -15.1% | 7.7% | 11.97% |
| 3-Year Return | -11.6% | 21.02% | 72.07% |
| Dec '22 | Dec '23 | Dec '24 | ||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Cost of Revenue | 110.00K | 97.00K | 16.00K | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.18,"profit":true},{"date":"2024-12-31","value":14.55,"profit":true}] | ||
| Gross Profit | (110.00K) | (97.00K) | (16.00K) | [{"date":"2022-12-31","value":-11000000,"profit":false},{"date":"2023-12-31","value":-9700000,"profit":false},{"date":"2024-12-31","value":-1600000,"profit":false}] | ||
| Gross Margin | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Operating Expenses | 11.36M | 7.42M | 22.79M | [{"date":"2022-12-31","value":49.87,"profit":true},{"date":"2023-12-31","value":32.54,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | ||
| Operating Income | (11.36M) | (7.42M) | (22.79M) | [{"date":"2022-12-31","value":-1136300000,"profit":false},{"date":"2023-12-31","value":-741500000,"profit":false},{"date":"2024-12-31","value":-2278500000,"profit":false}] | ||
| Total Non-Operating Income/Expense | (2.08M) | 1.63M | 4.61M | [{"date":"2022-12-31","value":-45.13,"profit":false},{"date":"2023-12-31","value":35.35,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] | ||
| Pre-Tax Income | (13.56M) | (7.21M) | (20.59M) | [{"date":"2022-12-31","value":-1356400000,"profit":false},{"date":"2023-12-31","value":-720800000,"profit":false},{"date":"2024-12-31","value":-2058800000,"profit":false}] | ||
| Income Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income After Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income From Continuous Operations | (13.56M) | (7.21M) | (20.59M) | [{"date":"2022-12-31","value":-1356400000,"profit":false},{"date":"2023-12-31","value":-720800000,"profit":false},{"date":"2024-12-31","value":-2058800000,"profit":false}] | ||
| Income From Discontinued Operations | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Net Income | (13.56M) | (7.21M) | (20.59M) | [{"date":"2022-12-31","value":-1356400000,"profit":false},{"date":"2023-12-31","value":-720800000,"profit":false},{"date":"2024-12-31","value":-2058800000,"profit":false}] | ||
| EPS (Diluted) | - | - | (0.43) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-43.5,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
| AARD | |
|---|---|
| Cash Ratio | 11.77 |
| Current Ratio | 12.03 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AARD | |
|---|---|
| ROA (LTM) | -30.81% |
| ROE (LTM) | -48.06% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AARD | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AARD | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 2.16 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Aardvark Therapeutics, Inc. Common Stock (AARD) share price today is $12.41
Yes, Indians can buy shares of Aardvark Therapeutics, Inc. Common Stock (AARD) on Vested. To buy
Yes, you can purchase fractional shares of Aardvark Therapeutics, Inc. Common Stock (AARD) via the Vested app. You can start investing in Aardvark Therapeutics, Inc. Common Stock (AARD) with a minimum investment of $1.
You can invest in shares of Aardvark Therapeutics, Inc. Common Stock (AARD) via Vested in three simple steps:
The 52-week high price of Aardvark Therapeutics, Inc. Common Stock (AARD) is $19.58. The 52-week low price of Aardvark Therapeutics, Inc. Common Stock (AARD) is $4.88.
The price-to-earnings (P/E) ratio of Aardvark Therapeutics, Inc. Common Stock (AARD) is
The price-to-book (P/B) ratio of Aardvark Therapeutics, Inc. Common Stock (AARD) is 2.16
The dividend yield of Aardvark Therapeutics, Inc. Common Stock (AARD) is 0.00%
The market capitalization of Aardvark Therapeutics, Inc. Common Stock (AARD) is $275.43M
The stock symbol (or ticker) of Aardvark Therapeutics, Inc. Common Stock is AARD
Consider the share price of Aardvark Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Aardvark Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Aardvark Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Aardvark Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Aardvark Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Aardvark Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
